Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 149,997
  • Shares Outstanding, K 39,577
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,720 K
  • 60-Month Beta 0.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.67
Trade ORIC with:

Options Overview Details

View History
  • Implied Volatility 81.82% ( +14.80%)
  • Historical Volatility 87.00%
  • IV Percentile 44%
  • IV Rank 24.49%
  • IV High 325.82% on 08/15/22
  • IV Low 2.68% on 02/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 3.66
  • Today's Open Interest 149
  • Open Int (30-Day) 4,500

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.56
  • Number of Estimates 4
  • High Estimate -0.55
  • Low Estimate -0.58
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +3.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.36 +60.59%
on 11/04/22
4.70 -19.36%
on 11/18/22
+1.12 (+41.95%)
since 10/28/22
3-Month
2.36 +60.59%
on 11/04/22
4.70 -19.36%
on 11/18/22
-0.17 (-4.29%)
since 08/26/22
52-Week
2.36 +60.59%
on 11/04/22
17.26 -78.04%
on 12/23/21
-10.54 (-73.55%)
since 11/26/21

Most Recent Stories

More News
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

ABBV : 158.43 (-0.75%)
AGLE : 1.2700 (+2.42%)
AKRO : 45.44 (-0.87%)
ORIC : 3.79 (+8.29%)
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab

Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.

ACAD : 14.77 (-2.25%)
AGLE : 1.2700 (+2.42%)
IMVT : 13.40 (+1.36%)
ORIC : 3.79 (+8.29%)
Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.

GILD : 85.21 (-1.22%)
MGNX : 6.49 (+9.63%)
ACAD : 14.77 (-2.25%)
ORIC : 3.79 (+8.29%)
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.

ACAD : 14.77 (-2.25%)
AGLE : 1.2700 (+2.42%)
NBSE : 0.2300 (-4.25%)
ORIC : 3.79 (+8.29%)
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

GSK : 33.76 (-0.68%)
PFE : 49.57 (+0.73%)
ACAD : 14.77 (-2.25%)
ORIC : 3.79 (+8.29%)
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review

The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.

REGN : 741.48 (+0.71%)
BAYRY : 14.4750 (-0.03%)
ACAD : 14.77 (-2.25%)
ORIC : 3.79 (+8.29%)
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.

BMRN : 98.66 (+1.80%)
ACAD : 14.77 (-2.25%)
ATRA : 4.09 (-2.15%)
ORIC : 3.79 (+8.29%)
Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern

Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.

ACAD : 14.77 (-2.25%)
ATRA : 4.09 (-2.15%)
AXSM : 74.74 (+31.54%)
ORIC : 3.79 (+8.29%)
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

ALNY : 209.20 (-1.65%)
ATRA : 4.09 (-2.15%)
ORIC : 3.79 (+8.29%)
ACHL : 1.9300 (+1.58%)
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

ATRA : 4.09 (-2.15%)
ALLO : 10.26 (-4.74%)
ORIC : 3.79 (+8.29%)
ACHL : 1.9300 (+1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 4.30
2nd Resistance Point 4.06
1st Resistance Point 3.93
Last Price 3.79
1st Support Level 3.56
2nd Support Level 3.32
3rd Support Level 3.19

See More

52-Week High 17.26
Fibonacci 61.8% 11.57
Fibonacci 50% 9.81
Fibonacci 38.2% 8.05
Last Price 3.79
52-Week Low 2.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar